Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9512

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: 5 Fraction Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Early Breast Cancer
Interventions: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 126
States / cities: Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: WATCHMAN FLX Pro LAAC Device; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more

Conditions: Solid Tumor, Unspecified, Adult, Lymphoma
Interventions: Single Arm; Drug
Lead sponsor: Cytosite Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Female Contraception
Interventions: Transdermal system containing progestin; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 56
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 40 more

Conditions: HIV/AIDS
Interventions: WISH Adherence, WISH Parenting; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 16 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: ATG Combined with Tacrolimus and Mini Methotrexate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hidradenitis Suppurativa (HS)
Interventions: povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 86
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 67 more

Conditions: Anterior Cruciate Ligament Reconstruction (ACLR)
Interventions: Bone-patellar Tendon-bone (BTB), Bone-patellar Tendon-bone (BTB) and Lateral Extra-Articular Tenodesis (LET); Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cystic Fibrosis
Interventions: VX-522 mRNA therapy, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Long Beach, California • Palo Alto, California + 9 more

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

SIMPLAAFY Clinical Trial

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

The Effect of Lateral Extra-Articular Tenodesis on Lower-Extremity Lean Mass Recovery Following Anterior Cruciate Ligament Reconstruction

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)